![Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of.pdf.jpg](/retrieve/58b81418-66b3-4eeb-ac49-ef80935a3192/Experience%20with%20tocilizumab%20in%20severe%20COVID-19%20pneumonia%20after%2080%20days%20of.pdf.jpg) | 2020 | Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of
follow-up: A retrospective cohort study | Moreno-Pérez, Oscar; Andres, Mariano; LEON-RAMIREZ, JOSE-MANUEL; Sánchez-Payá, José; Rodríguez, Juan Carlos; Sánchez, Rosario; García Sevila, Raquel; Boix, Vicente; Gil, Joan; Merino, Esperanza | ![](/image/openAccess.png) |
![Post-acute COVID-19 syndrome. Incidence and risk factors A Mediterranean cohort study.pdf.jpg](/retrieve/254d1d9e-2654-4a3e-9100-784cc021d452/Post-acute%20COVID-19%20syndrome.%20Incidence%20and%20risk%20factors%20A%20Mediterranean%20cohort%20study.pdf.jpg) | 2021 | Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study | Moreno-Pérez, Oscar; Merino, Esperanza; LEON-RAMIREZ, JOSE-MANUEL; Andres, Mariano; Ramos, Jose Manuel; Arenas-Jiménez, Juan; ASENSIO, SANTOS; Rosa, Sanchez; Ruiz-Torregrosa, Paloma; Galan, Irene; Scholz, Alexander; Amo, Antonio; González-delaAleja, Pilar; Boix, Vicente; Gil, Joan; On behalf of COVID19-ALC research group | ![](/image/openAccess.png) |